Skip to content
Subscriber Only

Ranbaxy Without Lipitor May Have to Rely on India Drug Sales

Ranbaxy Laboratories Ltd., counting on copies of Pfizer Inc.’s Lipitor to bolster U.S. sales, may have to rely more on India to improve growth because of delays resolving disputes with U.S. authorities.

Two Ranbaxy plants in India were placed under an export restriction in 2008 after the U.S. Food and Drug Administration found manufacturing failures. The decision banned sales of about 30 drugs in the U.S. and delayed approvals for new ones.